Development of Water-Soluble Prodrugs of the HIV-1 Protease Inhibitor KNI-727: Importance of the Conversion Time for Higher Gastrointestinal Absorption of Prodrugs Based on Spontaneous Chemical Cleavage-Reference-Cited by-同舟云学术

Development of Water-Soluble Prodrugs of the HIV-1 Protease Inhibitor KNI-727: Importance of the Conversion Time for Higher Gastrointestinal Absorption of Prodrugs Based on Spontaneous Chemical Cleavage

Published:2003-08-13 Issue:19 Volume:46 Page:4124-4135
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sohma Youhei¹,Hayashi Yoshio¹,Ito Tomoko¹,Matsumoto Hikaru¹,Kimura Tooru¹,Kiso Yoshiaki¹

Affiliation:

1. Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-Ku, Kyoto 607-8412, Japan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm030009m

Reference71 articles.

1. Kynostatin (KNI-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.

2. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Effect of Amine-geldanamycin Hybrids on Antiviral Activity against Influenza Virus;Journal of Pharmaceutical Research International;2021-04-14

2. Conformational, spectroscopic (FT-IR, FT-Raman, and UV-Vis), and molecular docking studies of N-(2-hydroxyethyl) succinimide;Journal of Molecular Structure;2019-11

3. Carvacrol prodrugs as novel antimicrobial agents;European Journal of Medicinal Chemistry;2019-09

4. Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties;European Journal of Medicinal Chemistry;2017-10

5. Advances in oral delivery of anti-cancer prodrugs;Expert Opinion on Drug Delivery;2016-07-06